



**REVIEW OF CORONARY HEART DISEASE RISK
IN HIV TREATMENT**

**ROUNDTABLE #3: ASSESSING THE POTENTIAL
IMPACT OF CVD RISK IN HIV TREATMENT**



Jur Strobos, M.D., J.D.
**Forum for Collaborative HIV
Research**



enhancing & facilitating HIV research

FORUM MISSION

- The Forum for Collaborative HIV Research is a public/private partnership including government agencies, industry, HIV researchers and clinicians, payors, foundations and the HIV patient advocacy community.

Our mission is to facilitate and enhance HIV research.



enhancing & facilitating HIV research

CARDIOVASCULAR RISK IN HIV INFECTION & TREATMENT 2010

- A series of Forum roundtables addressing:
 - Statistical issues
 - Biologic mechanisms
 - Clinical impact
- Public workshop
- Satellite symposium @ International AIDS Conference in Vienna



enhancing & facilitating HIV research

OBJECTIVES FOR RT # 3

- Develop a better understanding of the clinical impact of cardiovascular risk in HIV disease and treatment



SPECIFIC QUESTIONS

- When looking at CVD risk in HIV infected patients on ART, what are the appropriate control populations?
- What can we learn from other chronic inflammatory diseases?
- What is the role of the biomarkers in clinical decision making?
- What is the role of reducing (improving) biomarker profile in mitigating risk?
- How do clinicians best implement the findings in their clinics?



enhancing & facilitating HIV research

PROJECT STEERING COMMITTEE

- Jur Strobos (FCHR EC)
- Judy Aberg
- Dominique Costagliola
- Filip Josephson (EMA)
- Neil Poulter
- Peter Reiss
- Caroline Sabin
- Neil Shortman (HAART Oversight Committee)
- Jeff Taylor
- Courtney Fletcher
- Kendall Marcus (FDA)
- Amy Keller (FCHR)
- Veronica Miller (FCHR)



enhancing & facilitating HIV research

SUPPORT ACKNOWLEDGMENT

- Abbott
- Gilead
- HAART Oversight Committee
- Pfizer
- Tibotec
- ViiV